ES2640285T3 - Análogos de amilina humana - Google Patents
Análogos de amilina humana Download PDFInfo
- Publication number
- ES2640285T3 ES2640285T3 ES13723681.6T ES13723681T ES2640285T3 ES 2640285 T3 ES2640285 T3 ES 2640285T3 ES 13723681 T ES13723681 T ES 13723681T ES 2640285 T3 ES2640285 T3 ES 2640285T3
- Authority
- ES
- Spain
- Prior art keywords
- diacid
- amylin
- binding
- glu
- func
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 title abstract description 14
- 229920001184 polypeptide Polymers 0.000 abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 30
- 238000001525 receptor binding assay Methods 0.000 abstract description 6
- 108020003175 receptors Proteins 0.000 abstract description 6
- 102000005962 receptors Human genes 0.000 abstract description 6
- 101000741435 Homo sapiens Calcitonin receptor Proteins 0.000 abstract description 3
- 125000001424 substituent group Chemical group 0.000 abstract description 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 154
- -1 19-carboxynonadecanoylamino Chemical group 0.000 description 120
- 230000004048 modification Effects 0.000 description 104
- 238000012986 modification Methods 0.000 description 104
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 90
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 69
- 150000001875 compounds Chemical class 0.000 description 63
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 45
- 102000009027 Albumins Human genes 0.000 description 24
- 108010088751 Albumins Proteins 0.000 description 24
- 235000012631 food intake Nutrition 0.000 description 20
- 230000010933 acylation Effects 0.000 description 15
- 238000005917 acylation reaction Methods 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 14
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 14
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 description 9
- 101150088826 arg1 gene Proteins 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 101100404023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-14 gene Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108010029667 pramlintide Proteins 0.000 description 2
- 229960003611 pramlintide Drugs 0.000 description 2
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12164692 | 2012-04-19 | ||
| EP12164692 | 2012-04-19 | ||
| US201261637806P | 2012-04-24 | 2012-04-24 | |
| US201261637806P | 2012-04-24 | ||
| PCT/EP2013/058165 WO2013156594A1 (en) | 2012-04-19 | 2013-04-19 | Human amylin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2640285T3 true ES2640285T3 (es) | 2017-11-02 |
Family
ID=49382960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13723681.6T Active ES2640285T3 (es) | 2012-04-19 | 2013-04-19 | Análogos de amilina humana |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP2838914B1 (enExample) |
| JP (1) | JP6227629B2 (enExample) |
| CN (1) | CN104395338B (enExample) |
| ES (1) | ES2640285T3 (enExample) |
| PL (1) | PL2838914T3 (enExample) |
| WO (1) | WO2013156594A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| CN107567459B (zh) * | 2015-03-18 | 2021-09-24 | 西兰制药公司 | 胰淀素类似物 |
| CN106928086B (zh) * | 2015-12-31 | 2019-05-31 | 深圳翰宇药业股份有限公司 | 一种长链化合物的制备方法 |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| TWI847306B (zh) | 2017-08-24 | 2024-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | Ｇｌｐ-１組成物及其用途 |
| CN110467666A (zh) * | 2019-09-17 | 2019-11-19 | 湖北强耀生物科技有限公司 | 一种新型胰岛淀粉样多肽的合成方法 |
| BR112022013795A2 (pt) | 2020-02-18 | 2022-09-13 | Novo Nordisk As | Composição farmacêutica líquida, e, kit |
| CR20220641A (es) * | 2020-05-15 | 2023-01-19 | Lilly Co Eli | Compuestos de insulina acilada de acción temporal prolongada |
| WO2022120547A1 (zh) * | 2020-12-08 | 2022-06-16 | 通化安睿特生物制药股份有限公司 | 纯化重组蛋白的方法 |
| TW202400632A (zh) * | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| AR132977A1 (es) | 2023-06-15 | 2025-08-13 | Novo Nordisk As | Formulaciones farmacéuticas que comprenden una ciclodextrina |
| TW202545982A (zh) * | 2024-02-07 | 2025-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 胰島澱粉樣多肽類似物及其醫藥用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| ES2356595T3 (es) * | 1998-02-13 | 2011-04-11 | Amylin Pharmaceuticals, Inc. | Nuevos compuestos de actividad mixta de la amilina. |
| AU2005295043A1 (en) * | 2004-10-08 | 2006-04-20 | Amylin Pharmaceuticals, Inc. | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them |
| WO2007104789A2 (en) * | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| WO2010046357A1 (en) | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
| EP2389388B1 (en) * | 2009-01-22 | 2017-03-08 | KeyBioscience AG | Treatment for obesity |
-
2013
- 2013-04-19 EP EP13723681.6A patent/EP2838914B1/en active Active
- 2013-04-19 ES ES13723681.6T patent/ES2640285T3/es active Active
- 2013-04-19 PL PL13723681T patent/PL2838914T3/pl unknown
- 2013-04-19 EP EP16173530.3A patent/EP3109256A1/en not_active Withdrawn
- 2013-04-19 CN CN201380032197.0A patent/CN104395338B/zh active Active
- 2013-04-19 JP JP2015506251A patent/JP6227629B2/ja active Active
- 2013-04-19 WO PCT/EP2013/058165 patent/WO2013156594A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL2838914T3 (pl) | 2017-11-30 |
| CN104395338A (zh) | 2015-03-04 |
| JP6227629B2 (ja) | 2017-11-08 |
| EP2838914B1 (en) | 2017-06-14 |
| CN104395338B (zh) | 2019-05-10 |
| JP2015514737A (ja) | 2015-05-21 |
| EP3109256A1 (en) | 2016-12-28 |
| WO2013156594A1 (en) | 2013-10-24 |
| EP2838914A1 (en) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2640285T3 (es) | Análogos de amilina humana | |
| PE20140159A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| JP5755398B2 (ja) | 伸長されたｇｌｐ−１化合物 | |
| EP3129041B1 (en) | Double-acylated glp-1 compounds | |
| JP5019466B2 (ja) | グルカゴン様ペプチド−２アナログ | |
| PE20091393A1 (es) | Antagonistas de glucagon | |
| JP6701075B2 (ja) | アミリン類似体 | |
| PE20231639A1 (es) | Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1) | |
| JP2016526012A5 (enExample) | ||
| US20110275559A1 (en) | Long-Acting Y2 and/or Y4 Receptor Agonists | |
| BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
| JP2019534248A (ja) | アミリン類似体 | |
| JP2010515686A (ja) | 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体 | |
| WO2009058734A4 (en) | Compounds exhibiting glucagon antagonist and glp-1 agonist activity | |
| JP2018510871A (ja) | アミリン類似体 | |
| CA2988500A1 (en) | Selective pyy compounds and uses thereof | |
| JP2007537142A (ja) | アルブミン様物質に結合した新規のｇｌｐ−１類似物 | |
| PE20140186A1 (es) | Analogos de glucagon que presentan actividad de receptor de gip | |
| EP0763061A1 (de) | Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung | |
| JP2008533105A (ja) | アシル化ｇｌｐ−１化合物 | |
| ATE541582T1 (de) | Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen | |
| EP2846823A1 (en) | Double-acylated glp-1 derivatives | |
| RU2018107727A (ru) | Новые производные инсулина и их медицинские применения | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| US20200353088A1 (en) | Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof |